|
Dawnrays Pharmaceutical (Holdings) Ltd is a pharmaceutical company focused on the development and production of generic drugs and antibiotics. The company operates an integrated production system covering intermediates, bulk medicines, and powder for injection preparations. Its business strategy involves leveraging its generic drug foundation to expand into the research and development of small molecules and small nucleic acid drugs through collaborative R&D and mergers. The company serves the Chinese market, addressing demand driven by population aging and chronic disease prevalence. It maintains manufacturing facilities in Suzhou and Lanzhou, which are undergoing upgrades to meet the latest regulatory standards and optimize production costs. Summarised from the company's own disclosures, fiscal year ended Apr 2026 |
Industry Drug Manufacturers - General | Homepage dawnrays.com |
| Sector Healthcare | IR page dawnrays.com/Investor | |
|
Tags
generic drugs, antibiotics, small molecules, small nucleic acid drugs, bulk medicines, intermediates, powder for injection, Suzhou Dawnrays, Lanzhou Dawnrays
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | HK$ 1.38B |
| P/E | 5.77 |
| P/BV | — |
| P/S | 1.02 |
| P/OCF | 3.40 |
| P/FCF | — |
| Dividend yield | 6.9% |
| Turnover / mcap | 0.01% |
| Returns | |
|---|---|
| ROE | 6.4% |
| ROI | 6.2% |
| ROIC | 6.2% |
| Profit margin | 17.4% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | No |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | No |
| Buying back stock | — |
| Diluting (TTM) | No |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 0 |
| Quality score | 26.7% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.231B | 1.06B | 1.151B | 1.278B | 1.165B | 1.024B | 950.007M | 948.938M | 882.483M | 824.351M | 985M | 783.803M | 914.973M | 856.539M | 1.081B | 1.287B |
| Net profit | 213.971M | 564.94M | 326M | 358.057M | 358.175M | 268.13M | 255.43M | 303.96M | 292.978M | 265.917M | 302.198M | 205.145M | 153.099M | 114.506M | 146.307M | 166.84M |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpPrompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.